A recurrent, hotspot mutation, p.Leu129Gln in CYSLTR2, an oncogene driver in uveal melanoma and leptomeningeal melanocytic tumors, leads to the activation of endogenous Gαq signaling and contributes to tumor progression in vivo [18,19]. Here, CYSLTR2 is linked to neoplasm.